

Information Request			
Our Reference: STN: 125752/2			
Information Request #25			
Date: November 29, 2021			
То:	Michelle Olsen, Ph.D.  ModernaTX, Inc.  Email: Michelle.Olsen@modernatx.com		
From:	Joseph Kulinski, Ph.D. DVRPA/OVRR/CBER Email: Joseph.Kulinski@fda.hhs.gov		
Product: COVID-19 Vaccine, mRNA (SPIKEVAX)			
Subject: CMC Information			
We are reviewing the CMC information submitted in the BLA STN 125752 regarding the (b) (4) (b) (4) , mRNA-1273 LNP DS and mRNA-1273 Drug Product (DP) and have the following questions:			
The followi	ng comments pertain to the (b) (4):		
1. (b	(b) (4) (b) (4) (b) (4) (b) (4) (b) (4)		
2.	(b) (4)		
	(b) (4)		
a.	(b) (4)		
b.	(b) (4)		


(b) (4)

U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov

C.

(b) (4)

Page 2 - STN: 125752/2



## The following comment pertains to stability studies:

Please provide the most current stability data for (b) (4)
 (b) (4) mRNA-1273 DS and DP and for any scale B or clinical and developmental lots.

## The following clarification pertains to re-processing:

5.	The description of the manufacturing processes for the (b) (4)	
	(b) (4) , mRNA-1273 LNP DS, and mRNA	-1273 DP
	indicate that reprocessing is not performed for any process steps.	
	process validation protocols were included for a (b) (4) step for	( ) ( )
		Please clarify
	if implementation of re-processing to include (b) (4) requested for these process steps.	step will be
	requested for these process steps.	

Please confirm your receipt of this request, and provide your responses as an amendment to STN 125752 at your earliest convenience but no later than December 15, 2021.

Please contact me if you have questions and include Sudhakar Agnihothram (<u>sudhakar.agnihothram@fda.hhs.gov</u>) and Josephine Resnick (<u>josephine.resnick@fda.hhs.gov</u>) on all communications.